Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
1-프로판아민,3-(10,11-다이하이드로-5H-다이벤조(a,d)사이클로헵텐-5-일리덴)-N,N-다이메틸-,하이드로클로라이드
1-프로판아민,3-(10,11-다이하이드로-5H-다이벤조(a,d)사이클로헵텐-5-일리덴)-N,N-다이메틸-,하이드로클로라이드 · 아미트리프틸린하이드로클로라이드 · AMITRIPTYLINE HCL · amitid · endep · Amitriptyline Hydrochloride (200 mg) · deprex · Normaln
식별자 및 물리적 특성
| CAS No. | 549-18-8 |
|---|---|
| 분자식 | C20H24ClN |
| 평균 분자량 | 313.9 g/mol |
| 단동위원소 질량 | 313.1597275 g/mol |
| SMILES | CN(C)CCC=C1c2ccccc2CCc2ccccc21.Cl |
| InChIKey | KFYRPLNVJVHZGT-UHFFFAOYSA-N |
| PubChem CID | 11065 |
| ChEMBL | CHEMBL1200964 |
| ChEBI | CHEBI:2667 |
| EC No. | 208-964-6 |
| DTXSID | DTXSID9033187 |
| 현지명 | 1-프로판아민,3-(10,11-다이하이드로-5H-다이벤조(a,d)사이클로헵텐-5-일리덴)-N,N-다이메틸-,하이드로클로라이드 |
화학 및 물리적 성질
| 극성 표면적 | 3.2 |
|---|---|
| 수소 결합 공여자 수 | 1 |
| 수소 결합 수용자 수 | 1 |
| 회전 가능 결합 수 | 3 |
| 무거운 원자 수 | 22 |
| 형식 전하 | 0 |
| 복잡도 | 331 |
| 용해도 | >47.1 [ug/mL] (The mean of the results at pH 7.4)H2O: 용해성 |
| Collision Cross Section | 166.3 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards] |
| 녹는점 | 196-197°C |
| 인화점 | 11 °C |
| 저장 조건 | 2-8°C |
| 물리적 상태 | 가루 |
| pKa(산도 계수) | 9.4(at 25℃) |
| 색상 | 흰색에서 황백색까지 |
| pH | 4.5~6.0 (10g/l, 25℃) |
| 용해도 | 거의 투명함 |
| Merck | 14,487 |
| 헨리 상수 | 1.4×102 mol/(m3Pa) at 25℃, HSDB (2015) |
| BCS Class | 1 |
| InChI | InChI=1S/C20H23N.ClH/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H31H |
| InChIKey | KFYRPLNVJVHZGT-UHFFFAOYSA-N |
| SMILES | CN(CC/C=C1/C2=C(C=CC=C2)CCC2=C/1C=CC=C2)C.[H]Cl |
| EPA | Amitriptyline hydrochloride (549-18-8) |
화학적 성질
White to Off-White Solid
안전 및 규제
| GHS 분류 | This chemical does not meet GHS hazard criteria for 0.7% (1 of 136) of reports.DangerH301 (71.3%): Toxic if swallowed [Danger Acute toxicity, oral]H302 (27.9%): Harmful if swallowed [Warning Acute toxicity, oral]H318 (27.2%): Causes serious eye damage [Danger Serious eye damage/eye irritation]H319 (35.3%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]H361 (25.7%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]H361d (13.2%): Suspected of damaging the unborn child [Warning Reproductive toxicity]H362 (26.5%): May cause harm to breast-fed children [Reproductive toxicity, effects on or via lactation]H370 (40.4%): Causes damage to organs [Danger Specific target organ toxicity, single exposure]H400 (72.1%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]H410 (72.8%): Very toxic to aquatic life with long lasting effects [Warning Hazardous to the aquatic environment, long-term hazard]P203, P260, P263, P264, P264+P265, P270, P273, P280, P301+P316, P301+P317, P305+P351+P338, P305+P354+P338, P308+P316, P317, P318, P321, P330, P337+P317, P391, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 136 reports by companies from 21 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Reported as not meeting GHS hazard criteria per 1 of 136 reports by companies.There are 20 notifications provided by 135 of 136 reports by companies with hazard statement code(s).Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. |
|---|---|
| 규제 정보 | Status: Active Update: 04-04-2018 https://echa.europa.eu/registration-dossier/-/registered-dossier/24044Amitriptyline hydrochloride: Does not have an individual approval but may be used under an appropriate group standard |
| 기타 안전 정보 | IMAP assessments - 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-, hydrochloride: Human health tier I assessmentIMAP assessments - 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-, hydrochloride: Environment tier I assessment |
| Hazard Classes and Categories | Acute Tox. 3 (71.3%)Acute Tox. 4 (27.9%)Eye Dam. 1 (27.2%)Eye Irrit. 2 (35.3%)Repr. 2 (25.7%)Repr. 2 (13.2%)Lact. (26.5%)STOT SE 1 (40.4%)Aquatic Acute 1 (72.1%)Aquatic Chronic 1 (72.8%) |
| Treatment | Consider gastric lavage only if within one hour of a potentially fatal overdose. Give 50 grams of charcoal if within one hour of ingestion. Prolonged resuscitation may be successful in case of cardiac arrest. Give sodium bicarbonate in case of arrhythmias. (A311) |
| 건강 영향 | Some rare side effects include tinnitus, hypotension, mania, psychosis, heart block, arrhythmias, lip and mouth ulcers, extrapyramidal symptoms, depression, and hepatic toxicity.Amitriptyline exhibits strong anticholinergic activity, cardiovascular effects including orthostatic hypotension, changes in heart rhythm and conduction, and a lowering of the seizure threshold (A308, L1032). |
| 노출 경로 | Oral (A308) Rapidly and well absorbed following oral administration (bioavailability is 30-60% due to first pass metabolism). Peak plasma concentrations occur 2-12 hours following oral or intramuscular administration. |
| 독성 요약 | Amitriptyline is metabolized to nortriptyline which inhibits the reuptake of norepinephrine and serotonin almost equally. Amitriptyline inhibits the membrane pump mechanism responsible for uptake of norepinephrine and serotonin in adrenergic and serotonergic neurons. Pharmacologically this action may potentiate or prolong neuronal activity since reuptake of these biogenic amines is important physiologically in terminating transmitting activity. This interference with the reuptake of norepinephrine and/or serotonin is believed by some to underlie the antidepressant activity of amitriptyline. |
| Signs and Symptoms | Symptoms of overdose include abnormally low blood pressure, confusion, convulsions, dilated pupils and other eye problems, disturbed concentration, drowsiness, hallucinations, impaired heart function, rapid or irregular heartbeat, reduced body temperature, stupor, and unresponsiveness or coma. Side effects include: sedation, hypotension, blurred vision, dry mouth, constipation, urinary retention, postural hypotension, tachycardia, hypertension, ECG changes, heart failure, impaired memory and delirium, and precipitation of hypomanic or manic episodes in bipolar depression. Withdrawal symptoms include gastrointestinal disturbances, anxiety, and insomnia. |
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)Amitriptyline hydrochloridevLess-DILI-concern5Adverse reactionsDOI:10.1016/j.drudis.2016.02.015 |
| Toxicity Data | LD50: 350 mg/kg (Oral, Mouse) (A308) |
| 수질 위해 등급(WGK) | 3 |
| TSCA 등재 상태 | TSCA listed |
| RTECS 번호 | HO9450000 |
| 운송 번호(UN) | UN 2811 6.1/PG 3 |
| 독성 | LD50 in mice, rats (mg/kg): 350, 380 orally65, 75 i.p. (Tobe) |
| 관세 코드 | 29214990 |
| 위험 문구(R) | 23/24/25-36/37/38-42/43-63-39/23/24/25-11-50/53-36-22 |
| 위험 표시 | T,F,N,Xn |
| 안전 문구(S) | 22-26-36/37/39-45-36/37-16-61-60-7 |
| 포장분류 | III |
| 위험 등급 | 6.1(b)Acute Tox. 3 OralAquatic Acute 1Aquatic Chronic 1Eye Irrit. 2Repr. 2 |
| 기존화학 물질 | KE-10614 |
| 저장 분류 | 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects |
용도
개요
Amitriptyline (hydrochloride) (CRM) (Item No. 19031) is a certified reference material categorized as a tricyclic antidepressant. This product is intended for analytical forensic applications. This product is also available as a general research tool .
용도
Amitriptyline hydrochloride is a tricyclic antidepressant drug. Amitriptyline hydrochloride inhibits the norepinephrine and serotonin transporters but has a high affinity for α1-adrenergic, serotonin and muscarinic acetylcholine receptors.
일반 설명
Amitriptyline, 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine hydrochloride,5-(3-dimethylaminopropylidene)-10,11-dihydro-5Hdibenzo[a,d]cycloheptene hydrochloride (Elavil), is one ofthe most anticholinergic and sedative of the TCAs. Becauseit lacks the ring-electron–enriching nitrogen atom ofimipramine, metabolic inactivation mainly proceeds not at theanalogous 2-position but at the benzylic 10-position (i.e.,toluene-like metabolism predominates). Because of the 5-exocyclic double bond, E- and Z-hydroxy isomers are producedby oxidation metabolism. Conjugation produces excretablemetabolites. As is typical of the dimethyl compounds,N-demethylation occurs, and nortriptyline is produced, whichhas a less anticholinergic, less sedative, and more stimulantaction than amitriptyline. Nortriptyline is a SNERI; thecomposite action of drug and metabolite is nonselective.